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Aims The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and
undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary
heart disease (CHD).
Methods
and results
Of the theoretical estimated prevalence of 1/500 for heterozygous FH,,1% are diagnosed in most countries. Recently,
direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All
reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals
with FH, and up to 13-fold increased risk of CHD. Based on prevalences between 1/500 and 1/200, between 14 and
34 million individuals worldwide have FH. We recommend that children, adults, and families should be screened for
FH if a person or family member presents with FH, a plasma cholesterol level in an adult ≥8 mmol/L(≥310 mg/dL) or
a child ≥6 mmol/L(≥230 mg/dL), premature CHD, tendon xanthomas, or sudden premature cardiac death. In FH,
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low-density lipoprotein cholesterol targets are ,3.5 mmol/L(,135 mg/dL) for children, ,2.5 mmol/L(,100 mg/dL)
for adults, and ,1.8 mmol/L(,70 mg/dL) for adults with known CHD or diabetes. In addition to lifestyle and dietary
counselling, treatment priorities are (i) in children, statins, ezetimibe, and bile acid binding resins, and (ii) in adults,
maximal potent statin dose, ezetimibe, and bile acid binding resins. Lipoprotein apheresis can be offered in homozygotes
and in treatment-resistant heterozygotes with CHD.
Conclusion Owing to severe underdiagnosis and undertreatment of FH, there is an urgent worldwide need for diagnostic screening
together with early and aggressive treatment of this extremely high-risk condition.
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Introduction
Familial hypercholesterolaemia (FH) is a common genetic cause of
premature coronary heart disease (CHD) (i.e. ischaemic heart
disease), namely myocardial infarction and angina pectoris, due to
lifelong elevated plasma low-density lipoprotein (LDL) cholesterol
levels.1,2 If left untreated, men and women with heterozygous FH
(later referred to simply as FH, unless specified as heterozygous or
homozygous FH) with total cholesterol levels of 8–15 mmol/L
(310–580 mg/dL) typically develop CHD before age 55 and 60,
respectively, while homozygotes with total cholesterol levels of
12–30 mmol/L (460–1160 mg/dL) typically develop CHD very
early in life and if untreated die before age 20. However, once
diagnosed, heterozygotes can readily be treated with cholesterol-
lowering medication to attenuate development of atherosclerosis
and to prevent CHD.3
The extent of underdiagnosis and undertreatment of indivi-
duals in the general population with FH is largely unknown. It
is generally believed that among whites, 1/500 are heterozygous
for FH and 1/1 000 000 are homozygous1,2; however, even these
individuals are not diagnosed in most countries.4 Furthermore,
these prevalences likely represent underestimates and as cardio-
vascular disease is the leading cause of death worldwide.5
Indeed, many individuals and families with FH may simply be
overlooked among the huge number of individuals with any
CHD caused by more common risk factors, and as a conse-
quence be underdiagnosed and undertreated for genetically ele-
vated cholesterol levels.
The aim of the present consensus paper is to critically evaluate the
extent to which FH is underdiagnosed and undertreated worldwide.
Based on a consensus of the opinions of the experts in this panel and/
or on small studies, retrospective studies, and registries (level of evi-
dence C6), the EAS Consensus Panel proposes recommendations on
(i) how better to diagnose individuals and families with FH and
(ii) therapeutic strategies for best practice aimed to prevent CHD
in these extremely high-risk individuals and families. Importantly,
the effect of LDL cholesterol lowering on reduction in CHD and all-
cause mortality in individuals without FH is based on multiple rando-
mized clinical trials and meta-analyses7 (level of evidence A6). Details
of the levels of evidence specifically derived from FH studies can be
found elsewhere.8 This Consensus Statement is aimed at cardiologists,
endocrinologists, internists, paediatricians, generalpractitioners, clinic-
al biochemists, public health practitioners, health service planners,
other health professionals, and healthcare providers worldwide.
Underdiagnosis
FH was not attributed an independent code in the World Health Or-
ganisation International Classification of Diseases, making reliable
estimates of the number of individuals diagnosed with this condition
difficult. Of the roughly 200 countries/territories in the world, we
have therefore only been able to obtain estimates of the number of
individuals diagnosed with FH for the 22 countries/territories
shown in Figure 1. Upon inclusion of the 180 countries/territories
not listed in Figure 1, ,1% are diagnosed in most countries. The few
exceptions are 71% diagnosed in the Netherlands, 43% in Norway,
19% in Iceland, 13% in Switzerland, 12% in the UK, and 6% in Spain.
Even these numbers are somewhat unreliable; for example, it has
been estimated in Norway that roughly 1/300 have FH,9 and applying
this prevalence, instead of 1/500, would mean that 26% rather than
43% of individuals with FH are diagnosed in Norway.
To date, the prevalence of FH has not been assessed directly in an
unselected sample from the general population. Using the Copen-
hagen General Population Study,10 an unselected European general
population sample comprising 69 016 participants with heterozy-
gous FH was diagnosed using the Dutch Lipid Clinic Network
(DLCN) criteria (Table 1). The prevalence of individuals classified
with definite or probable FH combined (DLCN criteria, .5
points) was 1/200 (Figure 2).10 Interestingly, prevalences for defin-
ite or probable FH were similar for women and men below age 60; in
contrast, above age 60, more women than men were in this category.
These findings suggest that many men with FH had died at an earlier
age, as was also observed in a UK prevalence study.11
Based on extrapolations from these estimated 1/500–1/200 pre-
valences, there are between 14 and 34 million individuals with FH
worldwide (Figure 3). Furthermore, even higher prevalences are
observed in subpopulations with founder effects.2 Taken together,
these data strongly suggest that FH is vastly underdiagnosed in
most countries.
Undertreatment
Hitherto, data have not been reported either on the risk of CHD, or
on frequency of statin treatment, in FH individuals in a large sample
from the general population not subject to ascertainment bias.
Using the Copenhagen General Population Study,10 the prevalence
of CHD among definite/probable FH participants was 33%; only
48% of subjects with FH received statins. The risk of CHD was
increased 13-fold (95% CI: 10- to 17-fold) among individuals with
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definite/probable FH not receiving statins (Figure 4); similar findings
have been reported in FH cohort studies.12 Furthermore, the corre-
sponding increase in risk forCHDamong individualswithFHonstatin
was ten-fold (8- to 14-fold), suggesting that the dose of statin therapy
provided resulted in insufficient cholesterol-lowering medication,
and was introduced too late in life, when severe atherosclerosis
had already developed. Other studies also support massive under-
treatment of individuals with FH.3,12,13
Pathophysiology and genetics
FH is caused by mutations in genes encoding key proteins involved in
the LDL receptor endocytic and recycling pathways, leading to
decreased cellular uptake of LDL and increased plasma LDL choles-
terol concentrations1 (Figure 5). Within hepatocytes, cholesterol is
recycled or synthesized de novo, with 3-hydroxy-3-methylglutaryl
coenzyme A reductase being rate-limiting; statins block the activity
of this enzyme. Cholesterol is packaged into apolipoprotein
B-containing very low-density lipoproteins (VLDL), the intravascular
precursors of LDL, which in turn transports most cholesterol from
the liver to peripheral tissues. Regulated endocytosis of LDL via apo-
lipoprotein B by peripheral cells and hepatocytes occurs through
the LDL receptor and an adaptor protein (LDLRAP, alias ARH).14
Most LDL receptors recycle, although when proprotein convertase
subtilisin/kexin type 9 (PCSK9) is complexed to the LDL receptor, it
short-circuits its intracellular recycling from the endosome, thereby
reducing receptor numbers.
The life-threatening effects of both heterozygous and homozy-
gous FH are related to the resulting elevation in plasma LDL chol-
esterol, with consequent cholesterol retention in the arterial wall
and foam cell formation within the intima of arteries; such early
lesions typically progress to occlusive atherosclerosis with
angina pectoris and/or plaque rupture with CHD (i.e. myocardial
infarction).
Heterozygous FH is caused either by heterozygous loss-of-
function mutations in LDLR, heterozygous mutations in APOB
that affect the LDL receptor-binding domain of apolipoprotein
B, or heterozygous gain-of-function mutations in PCSK9.14
Currently, .1200 mutations have been documented worldwide
in LDLR15; these affect all functional domains of the LDL receptor
protein and include single-nucleotide mutations, copy number
variations, and splicing mutations throughout the LDLR gene. A
single mutation, Arg3500Gln, is the only common FH-related
mutation in APOB, while .20 different mutations have been
detected in PCSK9. Heterozygous LDLR, APOB, and PCSK9 muta-
tions are found in .90, 5, and 1%, respectively, of heterozy-
gous FH subjects with a causative mutation.2 The prevalence
varies geographically.
Homozygous FH results from homozygous, or more often, from
compound heterozygous mutations in either the LDLR or ARH
genes.16 Some rare subjects are ‘double heterozygotes’, which
means they carry mutations in two of the above-mentioned four
genes, usually leading to a phenotype that is intermediate between
heterozygous and homozygous FH.
Figure 1 Estimated per cent of individuals diagnosed with familial hypercholesterolaemia in different countries/territories, as a fraction of those
theoretically predicted based on a frequencyof 1/500 in the general population. As most countries do not have valid nationwide registries for familial
hypercholesterolaemia, several values in this figure represent informed estimates from clinicians/scientists with recognized expertise in and knowl-
edge of familial hypercholesterolaemia in their respective countries. Numbers were provided by Michael Livingston, Steve E. Humphries (UK),
Olivier S. Descamps (Belgium).
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Clinical vs. mutation diagnosis
Historically, heterozygous FH was diagnosed clinically and the
phenotypically most severe cases were detected, that is, those with
severe LDL cholesterol elevations, premature and familial CHD,
and tendon xanthomas.1 However, with the increased understanding
of the genetic causes of this disease, direct detection of mutations in
the LDLR, APOB, PCSK9, and LDLRAP genes is now available in many
countries. Such progress has led to the understanding that some
10–40%, depending on referral criteria, of those with a clinical diag-
nosis will not have a detectable causal mutation; rather, they have a
clinical diagnosis of FH, but not a mutation diagnosis (Figure 6).17,18
There may therefore be yet other key genes implicated in this
disease; alternatively, these individuals may present a polygenic
basis for their LDL cholesterol elevation without contributions
from any of the classical FH genes.
Conversely, genetic cascade testing from FH subjects with a
detected causative mutation has shown that, while on average,
relatives who carry the causative mutation have two-fold
higher mean LDL cholesterol levels compared with non-carrier
relatives, a significant proportion are below the clinical diagnos-
tic cut-off18 – 21 and thus they have a mutation diagnosis but not
a clinical diagnosis of FH (Figure 6).18 Such individuals may
possess other favourable genes and/or a lifestyle that reduces
the impact of the mutation, but because of their lifetime LDL
cholesterol exposure, they should still be offered appropriate
lipid-lowering therapy according to the LDL cholesterol
targets given later.
Whom to screen: how do we
recognize index cases?
Probands (index cases) should be identified according to the follow-
ing criteria:
(i) plasma total cholesterol ≥8 mmol/L (≥310 mg/dL) in an adult
or adult family member(s) (or .95th percentile by age and
gender for country),
(ii) premature CHD in the subject or family member(s),
(iii) tendon xanthomas in the subject or family member(s),
(iv) sudden premature cardiac death in a family member.
For child probands, criteria #(ii)–(iv) are identical to those of adults,
but criterion #(i) should be a plasma total cholesterol ≥6 mmol/L
(≥230 mg/dL) in a child or child family member(s) (or .95th per-
centile by age and gender for country). The highest likelihood of
detecting FH is in those with very high LDL cholesterol levels,
tendon xanthomas, and/or premature CHD in a family member.17
Drawing a family pedigree (Figure 7) is essential to evaluate the like-
lihood of FH (Table 1). In cases of probable or definite FH, cascade
screening using LDL cholesterol measurement in the family should
be conducted and the subject referred for genetic testing if available,
with subsequent cascade testing in the family if a causative mutation is
found. Initial family members to be tested are biological first-degree
relatives, namely parents, siblings, and children. Biological second-
degree relatives including grandparents, grandchildren, uncles,
aunts, nephews, nieces, and half-siblings should also be considered.
‘Premature CHD’ signifies CHD before age 55 in males and before
age 60 in female first-degree relatives, while in second-degree rela-
tives, the corresponding ages are 50 and 55.
Diagnosis
Diagnosis of FH relies on five criteria: family history, clinical history of
premature CHD, physical examination for xanthomas and corneal
arcus, very high LDL cholesterol on repeated measurements, and/
or a causative mutation detected by molecular genetics22 (Table 1).
Secondary causes of hyperlipidaemia must be excluded by determin-
ing that liver enzymes, renal function, and thyroid hormones are
normal and that there is no hyperglycaemia or albuminuria.
In addition to drawing a family pedigree (Figure 7), a systematic
physical examination for the presence of tendon and tuberous
Table 1 Dutch Lipid Clinic Network criteria
for diagnosis of heterozygous familial
hypercholesterolaemia in adults
Group 1: family history Points
(i) First-degree relative with known premature (,55 years,
men; ,60 years, women) coronary heart disease (CHD)
OR
1
(ii) First-degree relative with known LDL cholesterol .95th
percentile by age and gender for country
1
(iii) First-degree relativewith tendon xanthoma and/orcorneal
arcus OR
2
(iv) Child(ren) ,18 years with LDL cholesterol .95th
percentile by age and gender for country
2
Group 2: clinical history
(i) Subject has premature (,55 years, men; ,60 years,
women) CHD
2
(ii) Subject has premature (,55 years, men; ,60 years,
women) cerebral or peripheral vascular disease
1
Group 3: physical examination
(i) Tendon xanthoma 6
(ii) Corneal arcus in a person ,45 years 4
Group 4: biochemical results (LDL cholesterol)
.8.5 mmol/L (.325 mg/dL) 8
6.5–8.4 mmol/L (251–325 mg/dL) 5
5.0–6.4 mmol/L (191–250 mg/dL) 3
4.0–4.9 mmol/L (155–190 mg/dL) 1
Group 5: molecular genetic testing (DNA analysis)
(i) Causative mutation shown in the LDLR, APOB, or PCSK9
genes
8
A ‘definite FH’ diagnosis can be made if the subject scores .8 points. A ‘probable
FH’ diagnosis can be made if the subject scores 6 to 8 points. A ‘possible FH’
diagnosis can be made if the subject scores 3 to 5 points. An ‘unlikely FH’ diagnosis
can be made if the subject scores 0 to 2 points. Use of the diagnostic algorithm: per
group only one score, the highest applicable, can be chosen. For example, when
coronary heart disease and tendon xanthoma as well as dyslipidaemia are present
in a family, the highest score for family history is 2. However, if persons with
elevated LDL cholesterol levels as well as premature coronary heart disease are
present in a family, but no xanthoma or children with elevated LDL cholesterol
levels or a causative mutation are found, then the highest score for family history
remains 1.
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Figure2 Prevalence of definite or probable familial hypercholesterolaemia according to Dutch Lipid Clinic Network Criteria in the Copenhagen
General Population Study by 20-year age groups and by gender. Based on 69 016 individuals. This was originally reported as 1/137 but recalculation
suggested that the prevalence of definite or probable familial hypercholesterolaemia combined is closer to 1/200 (personal communication Børge G
Nordestgaard). FH, familial hypercholesterolaemia. Adapted from Benn et al.10
Figure 3 Estimated millions of individuals worldwide with familial hypercholesterolaemia by WHO regions and by income groups. Estimates are
shown for the theoretical frequency of heterozygous familial hypercholesterolaemia of 1/500 in the general population,1 as well as for the directly
detected frequency of 1/200 in the Danish population,10 a typical country in Northern Europe.
B.G. Nordestgaard et al.3482
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xanthomas and corneal arcus must be performed. Sonographic
evaluation of the Achilles tendons increases the rate of xanthoma
detection.23
Although total cholesterol levels are ≥8 mmol/L (≥6 mmol/L in
children), triglyceride and HDL cholesterol levels are generally
unremarkable. The presence of hypertriglyceridaemia does not
Figure4 Riskof coronary heart disease as a function of the Dutch Lipid Clinic Network Criteria for a diagnosis of familial hypercholesterolaemia in
individuals on or off statin from the general population. Data are based on 69 016 individuals from the Copenhagen General Population Study. CI,
confidence interval; FH, familial hypercholesterolaemia; CHD, coronary heart disease ¼ ischaemic heart disease. Adapted from Benn et al.10
Figure 5 Pathophysiology of heterozygous familial hypercholesterolaemia. LDL, low-density lipoprotein; PCSK9, proprotein convertase subtili-
sin/kexin type 9.
Guidance for clinicians to prevent coronary heart disease 3483
 by guest on July 15, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
exclude the FH diagnosis; other reasons for hypertriglyceridaemia
should however be evaluated and treated if necessary.24
The DLCN criteria are recommended in order to establish the
clinical diagnosis of FH (Table 1). Among individuals with a definite
or probable diagnosis of FH (DLCN . 5), and particularly those
with an obvious clinical diagnosis with xanthoma and/or high choles-
terol plus a family history of premature CHD, molecular genetic
testing is strongly recommended. When a causative mutation is
found in the index case, a genetic test should be offered to all first-
degree relatives (Figure 7).
Lifetime risk assessment and risk
factors
It should be stressed that risk calculators such as the European
SCORE or the US Framingham Risk Score are not appropriate for
FH subjects, as such individuals are at considerably higher risk due
to lifelong elevated LDL cholesterol levels (Figure 8). Nevertheless,
whether diagnosed clinically or through a causative mutation, not
all individuals with FH develop atherosclerosis and CHD to the
same extent. Thus, as observed for the development of any
CHD,25 other risk factors besideselevatedLDLcholesterol act tode-
termine the threshold for CHD (Figure 8), and risk factor counting is
critical to assess CHD risk.26 Importantly, as elevated LDL choles-
terol is the major problem in FH, this condition is dominated
by CHD, whereas cerebrovascular disease is more common in indi-
viduals with hypertension and atherosclerosis in the lower limbs is
more common among smokers.
The concept of a cumulative LDL cholesterol burden (Figure 8)
illustrates the importance of early treatment. The cumulative LDL
cholesterol burden of a 55-year-old person without FH is typically
160 mmol, a burden sufficient for CHD to develop (Figure 8; data
derived from20,21). For an individual with heterozygous FH, this
LDL cholesterol burden is reached by age 35 if untreated, by age
48 if treated since age 18, and by age 53 if treated since age 10. An un-
treated subject with homozygous FH will reach this level at age 12.5.
Men develop CHD before women; furthermore, hypertension,
smoking, diabetes, and high triglycerides/low HDL cholesterol24
are all well-established additional risk factors in FH. In addition, lipo-
protein(a) [Lp(a)] may be particularly elevated in clinically diagnosed
heterozygous or homozygous FH.27,28 Indeed, elevated Lp(a) is now
a well-established causal risk factor for cardiovascular disease irre-
spective of LDL cholesterol concentration.29,30 Elevated Lp(a) is
Figure 6 Overlap of clinical and mutation diagnosis of heterozygous familial hypercholesterolaemia. This figure illustrates the fractions of three
different clinical scenarios in a study from Spain,18 and therefore not necessarily the exact proportions for these three groups in other countries.
‘Mutation without clinical diagnosis’ means definite, probable, or possible familial hypercholesterolaemia with a familial hypercholesterolaemia-
causing mutation but with less severely elevated LDL cholesterol (i.e. below the diagnostic threshold). LDL, low-density lipoprotein cholesterol;
FH, familial hypercholesterolaemia.
Figure 7 Pedigree of a family with familial hypercholesterol-
aemia. Red and green colours indicate family members with and
without heterozygous familial hypercholesterolaemia. CHD, cor-
onary heart disease; LDL, low-density lipoprotein; FH, familial
hypercholesterolaemia.
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also an important cardiovascular risk factor in FH.31 Because elevated
Lp(a) significantly enhances risk of premature cardiovascular disease
in those already at extremely high risk due to FH, additional, aggres-
sive LDL lowering with statins and other drugs should be initiated
in FH individuals with high levels of Lp(a). In such individuals, and in
extreme cases with severe atherosclerosis and/or CHD, lipoprotein
apheresis should be considered.32,33
Asymptomatic atherosclerosis
To improve risk assessment, imaging techniques are recommended
to detect asymptomatic atherosclerosis in individuals at intermediate
risk in the 2012 European Society of Cardiology (ESC) Guidelines for
Cardiovascular Prevention.25 Although subjects with FH on average
are at much higher risk, risk within FH is sufficiently variable that as-
sessment of atherosclerosis should also be considered in asymptom-
atic FH subjects or in those whose family history is unclear. Imaging
techniques are also useful in detecting aortic valve calcification and
stenosis, which is particularly relevant in homozygous FH and in indi-
viduals with elevated Lp(a) levels.34
Techniques available to identify asymptomatic coronary athero-
sclerosis include exercise electro- and echocardiography, coronary
calcium score, and angiography by computed tomography.
Some,22,26 but not all,35 guidelines underscore the value of non-
invasive imaging of atherosclerosis in assessing and managing asymp-
tomatic FH subjects.
Exercise electro- or echocardiography should be considered for
risk assessment in adults with FH at very high risk; symptomatic
patients should be referred urgently for cardiac specialist review.
Coronary artery calcification is a surrogate marker for atheroscler-
osis, with the calcium score being proportional to atherosclerotic
plaque burden and cardiovascular disease risk.25 With the latest
techniques, radiation exposure is as low as 1 mSV. Coronary
artery calcification and the presence and severity of
atherosclerosis detected by computed tomography can identify
FH subjects with increased cardiovascular risk who may need
more intensive cholesterol-lowering therapy; however, absence
should not preclude cholesterol-lowering treatment, because
there would likely be diffuse, non-calcified plaques in such indivi-
duals. Importantly, presence of coronary calcium is not identical
with presence of relevant coronary lesions, because its specificity
regarding the potential presence of ≥50% stenosis is only 50%.25
Angiography by computed tomography is at present not recom-
mended for risk assessment.36
Cascade, opportunistic,
and universal screening
The most cost-effective approach for identification of new FH sub-
jects is cascade screening of family members of known index cases
(Figure 7). Index cases can be detected by opportunistic or targeted
systematic screening in primary care guided by a family history of pre-
mature CHD and hypercholesterolaemia, and among patients aged
,55/60 in men/women with CHD in hospital settings; the DLCN
criteria should be used to establish the clinical diagnosis (Table 1).
Universal screening of children has often been suggested but has so
far only been implemented in Slovenia and at the age of 5.37
Cascade screening using the protocol outlined in Table 2 has been
found to be feasible and acceptable to subjects with FH and to phy-
sicians.8,26,35 To be maximally cost-effective, cascade screening
should be systematic, centrally co-ordinated in a specialized centre
and carried out using a combination of plasma lipid profiles and
genetic testing. However, if the causative mutation is not known or
genetic testing is not available, screening can be performed using
the plasma lipid profile alone. Cascade testing in families with a
known causative mutation has been carried out very successfully in
the Netherlands over the last 15 years using trained genetic field
workers (Figure 1).
Figure8 LDLcholesterol burden in individuals withorwithout familial hypercholesterolaemiaas a functionof the ageof initiation of statin therapy.
Data derived from Huijgen et al.20 and Starr et al.21 LDL, low-density lipoprotein; LDL-C, LDL cholesterol; HDL-C, high-density lipoprotein chol-
esterol; CHD, coronary heart disease; FH, familial hypercholesterolaemia.
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Another promising but untested targeted approach would be to
screen all children for hypercholesterolaemia,37 for example at a
time of infant immunization, and then, for children with total choles-
terol .6 mmol/L (or .95th percentile), to perform ‘reverse’
cascade screening by testing their parents. This approach is based
on the fact that LDL cholesterol values differentiate much better
between mutation-negative and mutation-positive FH in children as
compared with adults.38 However, as parents may not always be
the blood relatives, DNA testing of children presents an ethical
dilemma.39 Also, given the relatively small fraction of the population
with FH, it is unclear whether such an approach would be feasible;
moreover, it would likely be associated with prohibitively high cost
and possibly with a high false positive rate.
LDL cholesterol targets
We recommend the following LDL cholesterol targets in FH, in ac-
cordance with recent ESC/EAS guidelines:
(i) children ,3.5 mmol/L (,135 mg/dL),
(ii) adults ,2.5 mmol/L (,100 mg/dL),6
(iii) adults with CHD or diabetes ,1.8 mmol/L (,70 mg/dL).6
These targets are for both heterozygous and homozygous FH
regardless of age. However, in children and adults with homozygous
FH, these values are extremely difficult to achieve with current
treatments.
Due to ethical reasons, no randomized trial has been conducted
documenting the benefit of lipid-lowering drug therapy specifically
in FH subjects; however, treatment targets are based on large
outcome lipid-lowering trials in persons without FH.7 LDL choles-
terol is the primary target of therapy and the reduction in both car-
diovascular and total mortality is proportional to the degree of
LDL cholesterol reduction, with every 1 mmol/L reduction being
associated with a corresponding 22% reduction in cardiovascular
mortality and a 12% reduction in total mortality over 5 years.7 All un-
treated individuals with FH above age 40 should be considered to be
at very high cardiovascular risk, as they have been exposed to ele-
vated LDL cholesterol levels since birth40 (Figure 8).
Treatment
All subjects with FH and their families should undergo intensive edu-
cation targeting lifestyle management,41 including intervention on
smoking, diet, and physical activity. It is imperative that smokers
quit smoking, and such individuals should be referred to a specialized
tobacco unit/programme when necessary. Advice to children and
young adults not to start smoking is especially important.
A certified dietitian/nutritionist should support implementation of
a healthy diet with the involvement of the whole family. A complete
record of dietary habits must be obtained, and recommendations for
a healthy diet should be individualized. Functional foods known to
lower LDL cholesterol, such as plant sterols and stanols, may be con-
sidered. The main objective of the nutritional advice is to avoid over-
weight and to reduce the amount of food and beverages with high
cholesterol, saturated fat, and transfat content. Regular physical exer-
cise must be implemented. In adults with FH, assessment of cardio-
vascular function is advisable before starting any significant exercise
programme.
Cholesterol-lowering drugs should be initiated immediately at
diagnosis in adults and strongly considered starting at age 8–10 in
childhood, along with lifestyle management. The priority for pharma-
cotherapy should be as follows:
Children:
(i) Statin,
(ii) Ezetimibe,
(iii) Bile acid-binding resin,
(iv) Lipoprotein apheresis in homozygotes.
Statins for children should only be those that have been shown to be
safe in this group.
Adults:
(i) Maximal potent statin dose,
(ii) Ezetimibe,
(iii) Bile acid-binding resins,
(iv) Lipoprotein apheresis in homozygotes and in treatment-
resistant heterozygotes with CHD.
Table 2 Cascade testing issues in familial hypercholesterolaemia
Notification of relatives at risk of familial hypercholesterolaemia should generally not be instituted without the consent of the index case.
National and local healthcare service protocols concerning disclosure of medical information without consent should be consulted.
A proactive approach that respects privacy, justice, and autonomy is required.
All material communicated to relatives and the telephone approach should be comprehensible and not cause alarm.
Pre-testing counselling should be offered to at risk family members of an index case prior to phenotypic or genetic testing.
If genetic testing detects a causative mutation, a definitive diagnosis of familial hypercholesterolaemia can be made in the tested individual particularly when the
phenotype also suggests familial hypercholesterolaemia (Table 1; Figure 6: clinical diagnosis and mutation diagnosis).
If genetic testing does not detect a causative mutation, the diagnosis of familial hypercholesterolaemia can be excluded, except when the clinical phenotype is
highly suggestive of familial hypercholesterolaemia (Figure 6: clinical diagnosis without mutation).
If genetic testing detects a causative mutation but the phenotype does not suggest familial hypercholesterolaemia, then a definitive diagnosis of familial
hypercholesterolaemia should not be made; however, the person and family should be monitored every 2–5 years for LDL cholesterol levels (Figure 6:
mutation without clinical diagnosis).
Genetic testing may have implications for insurance cover in certain countries.
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Maximal potent statin dose should be started at first consultation in
adults and could be either atorvastatin 80 mg, rosuvastatin 40 mg, or
pitavastatin 4 mg; simvastatin80 mg should notbe used, as this dose is
associated with elevated risk of myositis and rhabdomyolysis. We
recommend initiation with maximal potent statin dose in adults
with FH because among subjects with FH:
(i) ,1/20 achieve the recommended LDL cholesterol targets;
(ii) most need to decrease LDL cholesterol by at least 50%;
(iii) many receive statin doses insufficient to attain LDL cholesterol
targets;
(iv) many physicians do not uptitrate statin doses despite subopti-
mal treatment.
Clinical assessment of efficacy and safety is advisable 4–6 weeks after
initiating treatment.
Statins are the drug of first choice because of the huge and robust
bodyof evidence for statin-mediated reduction in major cardiovascu-
lar events.6,7,25 The introduction of statins has also reduced CHD
events in individuals with FH in observational studies,3,4 such that
with treatment before onset of CHD, survival without CHD can
be similar to that in the general population (Figure 9).
Despite use of the highest doses of potent statins, many subjects
with FH will not achieve the LDL cholesterol target with monother-
apy alone. Under these conditions, and despite lack of demonstrated
clinical benefit in FH of coadministration of the cholesterol absorp-
tion inhibitor, ezetimibe, we recommend this agent as an add-on
to statin therapy in view of few side effects and high compliance.
The statin–ezetimibe combination will decrease LDL cholesterol
by 60–70%. For subjects at very high risk with established CHD or
type 2 diabetes and with LDL cholesterol .1.8 mmol/L (.70 mg/
dL), a bile acid-binding resin (cholestyramine, colestipol, or coleseve-
lam) as a third drug is advised. In some FH patients and in some coun-
tries, use of pure niacin (up to 3 g/day) in association with a statin,
ezetimibe, or a bile acid-binding resin may be an option for additional
reduction of LDL and/or Lp(a). However, niacin in the form of Tre-
daptive is no longer available.
In FH subjects with elevated triglycerides and lowHDL cholesterol
or with triglycerides .5.7 mmol/L (.500 mg/dL), maximal potent
statin dose combined with fibrates can be considered, in particular
fenofibrate given its satisfactory drug–drug interaction profile24
and effect on LDL cholesterol reduction in FH.42 Fenofibrate can
also lower LDL cholesterol when triglycerides are normal and may
be used if other drugs cannot be tolerated or are unavailable.
Details of the efficacy, safety, and management of lipid-lowering
drugs are described elsewhere.43
FH individuals with statin intolerance require specialized manage-
ment to ensure that several different statins have been tested when
possible and to combine (depending on the individual case) low
dose of statin, ezetimibe, and resins.
In individuals with FH in extreme cases at very high cardiovascular
riskwith CHD, and with very high LDL cholesterol levels despite drug
therapy or because of statin intolerance, adjunctive treatment with
lipoprotein apheresis should be considered; this is particularly rele-
vant for children with homozygous FH. Weeklyor bi-weekly lipopro-
tein apheresis can decrease LDL cholesterol and Lp(a) by 50–75%
and has clinical benefits in individuals with severe FH.32,33,44– 48 Lipo-
protein apheresis can be appropriately conducted at specialized lipid
clinics, and atcentres forhaemodialysis and forblood transfusion, and
elsewhere. Clinical thresholds for initiation of lipoprotein apheresis
may vary between countries.
Children with familial
hypercholesterolaemia
In FH, elevated cholesterol is already present at birth and results in
early atherosclerotic lesions. Our recommendations in children
with this condition rely on intervention trials in children showing
good tolerance and efficacy of statins in terms of reduction in LDL
cholesterol,49,50 together with reduced progression of subclinical
atherosclerosis.51,52
The optimal age range for screening is between 2 and 10 years, as
determined by optimal discrimination using cholesterol measure-
ment between children with and without FH. Currently, it is consid-
ered unreasonable to start a low-fat diet before age 2, and there are
no safety data on the use of statins before age 8–10. On the other
hand, the earlier screening and treatment are initiated, the greater
the benefit and compliance in the future.52
If total or LDL cholesterol is high, a second lipid profile after 2 or 3
months of dietary guidance, along with other biochemical analyses to
exclude secondary hyperlipidaemia (see above) and other risk
factors such as Lp(a), should be performed. Once hypercholesterol-
aemia has been detected in the child, it is important to establish its
vertical transmission through a family pedigree (Figure 7), as aware-
ness of the genetic nature may improve the compliance to treatment
of both the parents and the child.
For diagnosis in children with one parent with FH, an LDL choles-
terol level .3.5 mmol/L (.135 mg/dL) is strongly suggestive.
Genetic tests should be performed in all children of parents with
FH and a causative mutation, irrespective of whether or not they
Figure9 Kaplan–Meiercurveestimatesof cumulativeCHD-free
survival among individuals with familial hypercholesterolaemia
according to statin treatment (P, 0.001 for difference). Based on
413 and 1537 Dutch subjects with heterozygous familial hyperchol-
esterolaemia on or off statin treatment. CHD, coronary heart
disease; FH, familial hypercholesterolaemia.Adapted fromVersmis-
sen et al.3
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have high LDL cholesterol; the ethical issues involved in genetic
testing of children must also be borne in mind.39 The absence of a
positive genetic test in the parents does not exclude FH in a child
with high cholesterol (Figure 6), and a clinical diagnosis is likely if a
child with LDL cholesterol .3.5 mmol/L has one parent with a
DLCN score.5 (Table 1). Importantly, many children in FH families
are on a healthy diet and thus have lower LDL cholesterol than
expected. In children, xanthomas and corneal arcus are not reliable
clinical criteria as they only appear later; however, if present, they
are suggestive of homozygous FH. When lifelong drug treatment is
under consideration, then genetic demonstration of a causative mu-
tation in LDLR, PCSK9 or APOB is optimal for the diagnosis of FH.
Dietary advice from a certified dietitian/nutritionist given to the
parents should start after age 2 of the child. Dietary recommenda-
tions are similar to those given to adults with FH; particular caution
is however needed to avoid caloric restriction (if weight is normal)
and to monitor the growth curve.
Priorities for cholesterol-lowering drugs in children are given
earlier. However, it is unknown at what age atherosclerotic lesions
become irreversible, only short-term follow-up data are available
that low dosages of statins are safe in children, and there is no long-
term study evaluating the cardiovascular benefit of cholesterol-
lowering drugs in children. Therefore, as is common in paediatrics,
the therapeutic decision is based on extrapolation from adult
studies and on short-term paediatric studies evaluating the safety
and the efficacy of pharmacotherapy on LDL cholesterol lowering
or intermediate endpoints.52 Thus, a registry of statin-treated chil-
dren to collect meaningful follow-up data is urgently needed.
Studies in children have shown this medication to be safe when
started from age 8 to 10 and, based on the graphical assumption in
Figure 8, we therefore recommend initiation of statin therapy at age
8–10, that is, when the diagnosis of FH is supported by a genetic
test or by strong clinical arguments including LDL cholesterol
.3.5 mmol/L (.135 mg/dL). As mentioned earlier, the LDL choles-
terol target in children is,3.5 mmol/L (,135 mg/dL); however, the
presence of very high LDL cholesterol or additional cardiovascular
risk factors (Figure 8) may lower this target or the age at initiation
of statin therapy. Importantly, lipoprotein apheresis should be
offered in children with homozygous FH.32,33,44– 47 Despite initial en-
thusiasm, the therapeutic potential of double heart– liver transplant-
ation in children with homozygous FH should be considered with
caution.
Cost-effectiveness
Individualswith FHwill incurcosts to thehealthcare systemover their
lifetime; if unidentified, these may include the cost of the premature
CHD they are likely to suffer (Figure 9). If treated however, such costs
will include the budget for cholesterol-lowering therapies and for the
healthcare professionals that diagnose and treat them. Healthcare
economic modelling has demonstrated that there are considerable
overall savings in identifying and appropriately treating subjects
with FH.53 For individuals in whom the causative mutation has been
found, cascade testing of their relatives using genetic testing is
highly cost-effective, as roughly 50% will have inherited the mutation.
Because of their lifelong burden of LDL cholesterol accumulation
(Figure 8), subjects with FH warrant intensive cholesterol-lowering
therapy and, even if more expensive agents are used, it remains cost-
effective.54
The cost per Life Year Gained for genetic cascade testing and in-
tensive statin therapy in FH is E3–4000, which compares very fa-
vourably with mammography for breast cancer screening.55
High-intensity lipid-lowering statin therapy would lead to 101
fewer cardiovascular deaths per 1000 FH individuals treated, and
when extrapolating to the 500 million population of the EU (with
an estimated 1 000 000 FH subjects), roughly E4700 million could
be saved from avoidance of cardiovascular events if all relatives of
index cases were identified and treated optimally over a 55-year
period, equating to an economy of E86 million per year.56
Novel therapies
Attainment of LDL cholesterol targets over time is imperative in FH
subjects, to reduce cumulative lifetime risk40 (Figures 8 and 9). Statin
therapy is often inadequate for this goal.10 Novel, well-tolerated
therapeutic strategies as add-ons to statin therapy or as sole drugs
in case of statin intolerance are therefore essential in FH. New
classes of efficacious, LDL- and Lp(a)-lowering agents are currently
at advanced stages of development, including therapies targeting
PCSK9, anti-sense oligonucleotides targeting APOB, microsomal tri-
glyceride transfer protein inhibitors, and cholesteryl ester transfer
protein inhibitors. Additional studies on their long-term safety and
efficacy, together with tolerability over time are, however, needed.
Diagnostic and treatment
summary
We recommend that most individuals with FH should be treated in
primary care, preferably in a family context, while complex cases in-
cluding children should be referred to specialized lipid or FH clinics.
However, as FH management in primary care poses major challenges
such as appropriate use of genetic testing, frequent requirement for
polypharmacy, specialist knowledge of non-invasive testing, and
complex organizational requirements for family cascade screening,
‘shared care’ between primary care and specialized lipid or FH
clinics is another attractive option. In most countries, there is an
urgent need for education of physicians to deal with FH, to establish
networks of Lipid/FH clinics, and to establish laboratories for genetic
screening and testing, preferably in a concerted manner (Figure 10).
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